Search

Your search keyword '"Gilbert J."' showing total 917 results

Search Constraints

Start Over You searched for: Author "Gilbert J." Remove constraint Author: "Gilbert J." Topic business.industry Remove constraint Topic: business.industry
917 results on '"Gilbert J."'

Search Results

1. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

2. Roadmap to 2030 for Drug Evaluation in Older Adults

3. Hypothalamic–Pituitary–Adrenal Axis Pediatric Safety Studies Submitted to the FDA

4. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir

5. Echocardiographic diagnosis of left ventricular diastolic dysfunction: Impact of coronary artery disease

6. The Vasomotor Response to Dopamine Is Altered in the Rat Model of <scp>l</scp> ‐dopa‐Induced Dyskinesia

7. Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives

8. The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More

9. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs

10. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012–2018

11. Dosing Recommendations for Pediatric Patients With Renal Impairment

12. Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?

13. Association Between Serological Responses to Two Zoonotic Ruminant Pathogens and Esophageal Squamous Cell Carcinoma

14. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy‐Induced Nausea and Vomiting

15. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States

16. Ontogeny equations with probability distributions for anthropomorphic measurements in preterm and term neonates and infants for use in a PBPK model

17. Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life

18. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry

19. Pediatric Drug Development Studies for Familial Hypercholesterolemia Submitted to the US Food and Drug Administration Between 2007 and 2020

20. The Society for Obstetric Anesthesia and Perinatology Coronavirus Disease 2019 Registry: An Analysis of Outcomes Among Pregnant Women Delivering During the Initial Severe Acute Respiratory Syndrome Coronavirus-2 Outbreak in the United States

21. Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling

22. Applying the Noninferiority Paradigm to Assess Exposure‐Response Similarity and Dose Between Pediatric and Adult Patients

23. Neonatal and Pediatric Dose Selection: Quo Vadis?

24. Development and Validation of a Patient-Reported Outcome Measure of Ataxia

25. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma

26. Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration

27. Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals

28. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020

29. Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products

30. Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting

31. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019

32. Chronic Q Fever with Vascular Involvement: Progressive Abdominal Pain in a Patient with Aortic Aneurysm Repair in the United States

33. Renal Clearance in Newborns and Infants: Predictive Performance of Population‐Based Modeling for Drug Development

34. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

35. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Early thyroidectomy in multiple endocrine neoplasia: a four decade experience

36. Trauma and Children

37. Trauma and Substance Abuse

38. Family Therapy for Treating Trauma

39. Evidence-Based Trauma Treatments

40. The RACE to Develop New Targeted Therapies for Children With CNS Tumors

41. Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes

42. Scientific and Regulatory Considerations for an Ontogeny Knowledge Base for Pediatric Clinical Pharmacology

43. Assessing <scp>CYP</scp> 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

44. Increasing Implementation Fidelity for School-Based Drug Abuse Prevention: Effectiveness of Enhanced Training and Technical Assistance

45. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma

46. Trends in Q fever serologic testing by immunofluorescence from four large reference laboratories in the United States, 2012–2016

47. Vital Signs: Trends in Reported Vectorborne Disease Cases — United States and Territories, 2004–2016

48. Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA

49. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

50. Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration

Catalog

Books, media, physical & digital resources